Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Changchun, China Clinical Trials

A listing of Changchun, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL)

Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID) were designed for assessment of safety, as well as PK/PD profiles. The recommended dose of phase II clinical study will be determined according to the Part I results. Part II: Dose expansion -Anti-tumor ...

Phase

2.18 miles

Learn More »

A Study to Investigate ICP-022 in Chinese Patients With CLL/ SLL

Part I: Safety evaluation -2 regimens of ICP-022 (High and low dose QD) are designed for safety assessment. The recommended dose of phase II clinical study will be determined according to the Part I results. Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R CLL/SLL will ...

Phase

2.18 miles

Learn More »

Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors

This study is a single arm, open clinical trial. Consecutive patients with leptomeningeal metastases from malignant solid tumors are enrolled into this study. Concomitant regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks ...

Phase

3.46 miles

Learn More »

The Study to Evaluate JS001 in Patients With Advanced GC ESCC NPC HNSCC

Overall Design: This is a multicenter, open-label, phase Ib/II clinical study of recombinant humanized anti-programmed death receptor 1 (PD-1) monoclonal antibody for injection (JS001) in patients with gastric adenocarcinoma (GC), esophageal squamous cell carcinoma (ESCC), nasopharyngeal carcinoma (NPC), or head and neck squamous cell carcinoma (HNSCC). On the basis of ...

Phase

4.21 miles

Learn More »